Structure Therapeutics Inc (GPCR)

$39.34 -0.83 (-2.07%)
Market Cap 2.86B
Revenue (ttm) 0.00
Net Income (ttm) -141.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 507,000
Avg Vol 875,470
Day's Range N/A - N/A
Shares Out 71.08M
Stochastic %K 62%
Beta -1.31
Analysts Strong Sell
Price Target $108.31

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
nlrmandate
nlrmandate May. 30 at 2:23 PM
$GPCR $VKTX @IM11 @dyrtydave cash burn has nothing to do with it. Management said in the last EC that the oral trial would be much shorter and smaller. Thus, my understanding is that they intend to use the maintenance trial data in designing the p3 oral trial. Maintenance reads out in September/October and its results will inform final oral trial design.
1 · Reply
dyrtydave
dyrtydave May. 29 at 10:41 PM
$VKTX $GPCR respectfully, this analysis is completely off base. VKTX is fully funded through ph3 for both SQ/oral (not sure where you think they'll run out in months), meaning BP isn't trying to wait them out at all because VKTX can simply raise funds following a ph3 data pump. the reason GPCR is a key buyout candidate is their eagerness for a deal and the fact it won't cost BP an arm and a leg. but the reality is GPCR is a bit of a half measure bolt on deal for BP; BPs looking for a transformative deal have only one target -- VKTX. that in and of itself creates the urgency you believe is lacking. i think the only barrier to a deal thus far is the valuation gap and VKTX's reluctance to lower their ask price. there are several catalysts in the 2H of 26 that should even further derisk VKTX and close the valuation gap, making a deal far more likely. it'll all depend on the strength of the data though.
2 · Reply
DG20
DG20 May. 29 at 9:06 PM
$GPCR $VKTX NVO is in a terrible spot. Their next drug (CagriSema) is less tolerable and results in less weightloss than Tirzepatide. Novo’s CEO has already been explicit they will be pursuing assets from other companies.
2 · Reply
biolover
biolover May. 29 at 8:57 PM
$GPCR $VKTX I don’t think this guy understands anything about drugs which is 90% of the whole BO thesis. Although a dump BP CEO could still pay a few billions for GPCR as CEO clearly wants to sell and hired Metsera guy, prior to any Lilly distaster with liver that will destroy GPCR
1 · Reply
IM11
IM11 May. 29 at 8:01 PM
$VKTX IMO, there is no urgency for BP to buyout $VKTX at this stage of Phase 3. BP will just let VKTX run out of money in a few months and try to swoop in and buy them before VKTX has to dilute shares to raise more money. The one to watch IMO is $GPCR. Until they dose the first patient for Phase 3 in early Aug, BP should have a strong desire to announce a buyout so that the buyer can setup & run Phase 3. Just my opinion on the current status of the two biotech front-runners that will likely be bought out sometime between next Monday and 2 years from now.... Just for fun though, I am going with JNJ to buyout VKTX and Roche or AbbVie to buyout GPCR. Roche already owes GPCR royalties for patent licensing, so they have ~$3 billion head-start on needing to acquire GPCR.
2 · Reply
IM11
IM11 May. 29 at 6:15 PM
$GPCR Anyone else here use ETrade? GPCR has been Position Closing Only blocked on ETrade since at least April 1st (possibly before that, I just hadn't tried to purchase before that). Per Reddit, looks like it was PCO restricted on ETrade in Aug of last year 2025 too. I was hoping that it was one of a few potential indicators that buyout negotiations could be in the works given that now until the first patient is dosed for Phase 3 is a prime buyout window, but if it happens often with GPCR and Etrade, than maybe it is a big nothing burger?
0 · Reply
murphylaw
murphylaw May. 29 at 3:38 PM
$GPCR big week coming up. Should be 50 next week after results announcements. Lilly buyout just around the corner!
0 · Reply
blocktrade
blocktrade May. 29 at 12:48 AM
$GPCR how many shares traded?
0 · Reply
Renohawk
Renohawk May. 28 at 3:00 PM
$VKTX $IBB $LLY $GPCR I have been a way for a while on VKTX, but the setup below is too enticing to ignore. A break above the 200 day at $33ISH and the massive short interest is going to be fuel for the fire. That sets up a quick move to $36. I expect either GPCR or VKTX to be acquired by end 0f 2026. But even if it is GPCR, VKTX is going along for the ride.
0 · Reply
BullYa
BullYa May. 28 at 1:48 PM
$GPCR ✅ 41~43 today ?
0 · Reply
Latest News on GPCR
Structure Therapeutics Announces Participation in Upcoming Investor Conferences

May 26, 2026, 4:05 PM EDT - 4 days ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026, 4:05 PM EDT - 23 days ago

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 23 days ago

Structure Therapeutics Earnings release: Q1 2026

Structure Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 23 days ago

Structure Therapeutics Quarterly report: Q1 2026

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Apr 27, 2026, 4:05 PM EDT - 4 weeks ago

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Canaccord starts Structure Therapeutics on oral weight loss pipeline

2026-04-27T12:58:41.000Z - 4 weeks ago

Canaccord starts Structure Therapeutics on oral weight loss pipeline

Structure Therapeutics initiated with a Buy at Canaccord

2026-04-27T10:00:27.000Z - 4 weeks ago

Structure Therapeutics initiated with a Buy at Canaccord

Structure Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 5 weeks ago

Structure Therapeutics Proxy statement: Proxy filing

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Apr 17, 2026, 11:20 AM EDT - 6 weeks ago

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

NVO OZEM

Structure Therapeutics appoints Matthew Lang as COO

2026-04-14T20:17:51.000Z - 6 weeks ago

Structure Therapeutics appoints Matthew Lang as COO

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Apr 14, 2026, 4:05 PM EDT - 6 weeks ago

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

2026-03-16T15:55:34.000Z - 2 months ago

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

2026-03-16T15:10:26.000Z - 2 months ago

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

LLY NVO

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Mar 16, 2026, 10:46 AM EDT - 2 months ago

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Structure Therapeutics Transcript: Study result

Mar 16, 2026, 8:30 AM EDT - 2 months ago

Structure Therapeutics Transcript: Study result

Structure Therapeutics Press release: Study result

Mar 16, 2026, 8:30 AM EDT - 2 months ago

Structure Therapeutics Press release: Study result

Structure Therapeutics Slides: Study result

Mar 16, 2026, 8:30 AM EDT - 2 months ago

Structure Therapeutics Slides: Study result

3 Companies at the Forefront of the GLP-1 Pill Wars

Mar 16, 2026, 7:44 AM EDT - 2 months ago

3 Companies at the Forefront of the GLP-1 Pill Wars

LLY VKTX

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

2026-03-16T11:22:17.000Z - 2 months ago

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

2026-03-02T11:26:56.000Z - 3 months ago

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

Structure Therapeutics price target lowered to $113 from $120 at Citizens

2026-02-27T10:55:51.000Z - 3 months ago

Structure Therapeutics price target lowered to $113 from $120 at Citizens

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Feb 26, 2026, 4:02 PM EST - 3 months ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Structure Therapeutics Annual report: Q4 2025

Feb 26, 2026, 4:00 PM EST - 3 months ago

Structure Therapeutics Annual report: Q4 2025

Structure Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 4:00 PM EST - 3 months ago

Structure Therapeutics Earnings release: Q4 2025

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 4 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

2026-01-30T15:51:54.000Z - 4 months ago

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

2026-01-22T11:51:35.000Z - 4 months ago

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 21, 2026, 10:05 AM EST - 4 months ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

2026-01-20T12:26:42.000Z - 4 months ago

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

Structure Therapeutics moved to Buy rating at Goldman Sachs

2026-01-19T22:30:27.000Z - 4 months ago

Structure Therapeutics moved to Buy rating at Goldman Sachs

LLY

Structure CEO Ray Stevens talks its obesity drug portfolio

Jan 15, 2026, 6:21 PM EST - 4 months ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

2026-01-14T18:05:20.000Z - 4 months ago

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

LLY NVO PFE TERN VKTX

Structure Therapeutics rises 14.1%

2026-01-13T17:05:46.000Z - 4 months ago

Structure Therapeutics rises 14.1%

Structure Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 4 months ago

Structure Therapeutics Slides: Corporate presentation

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

2025-12-19T13:45:27.000Z - 5 months ago

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671

2025-12-17T13:35:49.000Z - 5 months ago

Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671

Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley

2025-12-12T13:18:17.000Z - 6 months ago

Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 6 months ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 6 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 6 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 6 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure Therapeutics Transcript: Study Update

Dec 8, 2025, 8:30 AM EST - 6 months ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Dec 8, 2025, 8:30 AM EST - 6 months ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Dec 8, 2025, 8:30 AM EST - 6 months ago

Structure Therapeutics Slides: Study Update

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 6 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 6 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 6 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 7 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 7 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Structure Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

Structure Therapeutics Quarterly report: Q3 2025

Structure Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

Structure Therapeutics Earnings release: Q3 2025

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 7 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:45 AM EDT - 9 months ago

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 9 months ago

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 10 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Structure Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Structure Therapeutics Quarterly report: Q2 2025

Structure Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Structure Therapeutics Earnings release: Q2 2025

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 1 year ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 1 year ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Structure Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Earnings release: Q1 2025

Structure Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Quarterly report: Q1 2025

Structure Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Structure Therapeutics Proxy statement: Proxy Filing

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 1 year ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 1 year ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:00 PM EDT - 1 year ago

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Structure Therapeutics Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Annual report: Q4 2024

Structure Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q4 2024

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 10:30 AM EST - 1 year ago

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Transcript: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Transcript: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Quarterly report: Q3 2024

Structure Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q3 2024

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 9:10 AM EDT - 1 year ago

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 10:00 AM EDT - 1 year ago

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Structure Therapeutics Quarterly report: Q2 2024

Structure Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Structure Therapeutics Earnings release: Q2 2024

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 2 years ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 2 years ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 2 years ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 2 years ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 2 years ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 2 years ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Transcript: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Registration statement: Registration Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Registration statement: Registration Filing

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Structure Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Quarterly report: Q1 2024

Structure Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Earnings release: Q1 2024

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 2 years ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Structure Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Proxy statement: Proxy Filing

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 2 years ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 2 years ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 4:05 PM EST - 2 years ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Mar 8, 2024, 8:30 AM EST - 2 years ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Structure Therapeutics Annual report: Q4 2023

Mar 8, 2024, 7:00 AM EST - 2 years ago

Structure Therapeutics Annual report: Q4 2023

Structure Therapeutics Earnings release: Q4 2023

Mar 8, 2024, 7:00 AM EST - 2 years ago

Structure Therapeutics Earnings release: Q4 2023

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Jan 17, 2024, 3:40 PM EST - 2 years ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX TERN

nlrmandate
nlrmandate May. 30 at 2:23 PM
$GPCR $VKTX @IM11 @dyrtydave cash burn has nothing to do with it. Management said in the last EC that the oral trial would be much shorter and smaller. Thus, my understanding is that they intend to use the maintenance trial data in designing the p3 oral trial. Maintenance reads out in September/October and its results will inform final oral trial design.
1 · Reply
dyrtydave
dyrtydave May. 29 at 10:41 PM
$VKTX $GPCR respectfully, this analysis is completely off base. VKTX is fully funded through ph3 for both SQ/oral (not sure where you think they'll run out in months), meaning BP isn't trying to wait them out at all because VKTX can simply raise funds following a ph3 data pump. the reason GPCR is a key buyout candidate is their eagerness for a deal and the fact it won't cost BP an arm and a leg. but the reality is GPCR is a bit of a half measure bolt on deal for BP; BPs looking for a transformative deal have only one target -- VKTX. that in and of itself creates the urgency you believe is lacking. i think the only barrier to a deal thus far is the valuation gap and VKTX's reluctance to lower their ask price. there are several catalysts in the 2H of 26 that should even further derisk VKTX and close the valuation gap, making a deal far more likely. it'll all depend on the strength of the data though.
2 · Reply
DG20
DG20 May. 29 at 9:06 PM
$GPCR $VKTX NVO is in a terrible spot. Their next drug (CagriSema) is less tolerable and results in less weightloss than Tirzepatide. Novo’s CEO has already been explicit they will be pursuing assets from other companies.
2 · Reply
biolover
biolover May. 29 at 8:57 PM
$GPCR $VKTX I don’t think this guy understands anything about drugs which is 90% of the whole BO thesis. Although a dump BP CEO could still pay a few billions for GPCR as CEO clearly wants to sell and hired Metsera guy, prior to any Lilly distaster with liver that will destroy GPCR
1 · Reply
IM11
IM11 May. 29 at 8:01 PM
$VKTX IMO, there is no urgency for BP to buyout $VKTX at this stage of Phase 3. BP will just let VKTX run out of money in a few months and try to swoop in and buy them before VKTX has to dilute shares to raise more money. The one to watch IMO is $GPCR. Until they dose the first patient for Phase 3 in early Aug, BP should have a strong desire to announce a buyout so that the buyer can setup & run Phase 3. Just my opinion on the current status of the two biotech front-runners that will likely be bought out sometime between next Monday and 2 years from now.... Just for fun though, I am going with JNJ to buyout VKTX and Roche or AbbVie to buyout GPCR. Roche already owes GPCR royalties for patent licensing, so they have ~$3 billion head-start on needing to acquire GPCR.
2 · Reply
IM11
IM11 May. 29 at 6:15 PM
$GPCR Anyone else here use ETrade? GPCR has been Position Closing Only blocked on ETrade since at least April 1st (possibly before that, I just hadn't tried to purchase before that). Per Reddit, looks like it was PCO restricted on ETrade in Aug of last year 2025 too. I was hoping that it was one of a few potential indicators that buyout negotiations could be in the works given that now until the first patient is dosed for Phase 3 is a prime buyout window, but if it happens often with GPCR and Etrade, than maybe it is a big nothing burger?
0 · Reply
murphylaw
murphylaw May. 29 at 3:38 PM
$GPCR big week coming up. Should be 50 next week after results announcements. Lilly buyout just around the corner!
0 · Reply
blocktrade
blocktrade May. 29 at 12:48 AM
$GPCR how many shares traded?
0 · Reply
Renohawk
Renohawk May. 28 at 3:00 PM
$VKTX $IBB $LLY $GPCR I have been a way for a while on VKTX, but the setup below is too enticing to ignore. A break above the 200 day at $33ISH and the massive short interest is going to be fuel for the fire. That sets up a quick move to $36. I expect either GPCR or VKTX to be acquired by end 0f 2026. But even if it is GPCR, VKTX is going along for the ride.
0 · Reply
BullYa
BullYa May. 28 at 1:48 PM
$GPCR ✅ 41~43 today ?
0 · Reply
BullYa
BullYa May. 28 at 1:41 PM
$GPCR ✅💨↗️
0 · Reply
Theflash88
Theflash88 May. 27 at 8:38 PM
$GPCR Can we stay above $40 till it gets bought out!!??
0 · Reply
Bbbb44444
Bbbb44444 May. 27 at 2:12 PM
$GPCR This thing has BO written all over it, but who will it be?
1 · Reply
parrotineum
parrotineum May. 24 at 6:20 PM
$GPCR up 60% since when? Did they mean down 60%?
0 · Reply
LewisDaKat
LewisDaKat May. 24 at 3:00 PM
$GPCR This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million https://marketwirenews.com/stock/gpcr/news/this-biotech-is-up-60-a-top-healthcare-fund-just-bou-7865289651553204.html?utm_source=stocktwits
0 · Reply
Bbbb44444
Bbbb44444 May. 22 at 4:22 PM
$GPCR Is the main differentiator here the efficacy couple with a better side effect profile? Retatrutide looks very effective, but similar side effects as other GLP-1s.
2 · Reply
Bostonstrong32163
Bostonstrong32163 May. 22 at 1:48 PM
$ALT $GPCR $VKTX if this is true, look the fuck out. Absolute game changer . Amazing
1 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 22 at 1:44 PM
$GPCR ready for reversal. 70s. Mark it.
0 · Reply
Mendryl
Mendryl May. 22 at 1:23 PM
$GPCR Studies suggest Ozempic, Mounjaro may slow tumor progression, WSJ reports
0 · Reply
Theflash88
Theflash88 May. 22 at 11:42 AM
$ALT $VKTX $GPCR
1 · Reply
murphylaw
murphylaw May. 22 at 10:32 AM
$GPCR Should be bought out before summer end. Weight loss tablets are the way to go. Novo and Lilly will fight for this one. Novo getting desperate so would not surprise me if they go aggressively at current share price. 8 billion minimum buyout price.
1 · Reply
Wallst45
Wallst45 May. 22 at 10:20 AM
$GPCR like it here..very cheap buyout name as well
0 · Reply